Stool testing for the early detection of pancreatic cancer: Rationale and current evidence

Expert Review of Molecular Diagnostics

Volumn 8, Issue 6, 2008, Pages 753-759

  Haug, Ulrike ^a   Wente, Moritz N ^b   Seiler, Christoph M ^b   Jesnowski, Ralf ^a   Brenner, Hermann ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biomarker; Diagnosis; Early detection; Pancreatic cancer; Stool

Indexed keywords

CANCER SCREENING; EPIGENETICS; FECES ANALYSIS; GENETIC SCREENING; ONCOGENE K RAS; PANCREAS CANCER; REVIEW;

EARLY DETECTION OF CANCER; FECES; HUMANS; MASS SCREENING; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 56049114482     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.6.753     Document Type: Review

References (59)

1. Brenner H, Gondos A, Arndt V. Recent major progress in long-term cancer patient survival disclosed by modelled period analyses. J. Clin. Oncol. 25, 3274-3280 (2007).
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
3. Tsunoda T, Yamamoto Y, Kimoto M et al. Staging and treatment for patients with pancreatic cancer. How small is an early pancreatic cancer? J. Hepatobiliary Pancreat. Surg. 5, 128-132 (1998).
4. Ariyama J, Suyama M, Ogawa K et al. The detection and prognosis of small pancreatic carcinoma. Int. J. Pancreatol. 7, 37-47 (1990).
5. Canto MI, Goggins M, Yeo CJ et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin. Gastroenterol. Hepatol. 2, 606-621 (2004).
6. Canto MI, Goggins M, Hruban RH et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin. Gastroenterol. Hepatol. 4, 766-781 (2006).
7. DeWitt J, Devereaux B, Chriswell M et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann. Intern. Med. 141, 753-763 (2004).
8. Dewitt J, Devereaux BM, Lehman GA, Sherman S, Imperiale TF. Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review. Clin. Gastroenterol. Hepatol. 4, 717-725 (2006).
9. Ghadirian P, Boyle P, Simard A, Baillargeon J, Maisonneuve P, Perret C. Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int. J. Pancreatol. 10, 183-196 (1991).
10. Silverman DT, Schiffman M, Everhart J et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br. J. Cancer 80, 1830-1837 (1999).
11. De Angelis C, Repici A, Carucci P et al. Pancreatic cancer imaging: the new role of endoscopic ultrasound. JOP 8(Suppl. 1), 85-97 (2007).
12. Brune K, Abe T, Canto M et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am. J. Surg. Pathol. 30, 1067-1076 (2006).
13. Goggins M, Canto M, Hruban R. Can we screen high-risk individuals to detect early pancreatic carcinoma? J. Surg. Oncol. 74, 243-248 (2000). •• Addresses basic questions and provides important information for pancreatic cancer screening.
14. Laurell H, Bouisson M, Berthelemy P et al. Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples. World J. Gastroenterol. 12, 3344-3351 (2006).
15. Arvanitakis M, Van Laethem JL, Parma J, De Maertelaer V, Delhaye M, Deviere J. Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation. Endoscopy 36, 535-542 (2004).
16. Costentin L, Pages P, Bouisson M et al. Frequent deletions of tumor suppressor genes in pure pancreatic juice from patients with tumoral or nontumoral pancreatic diseases. Pancreatology 2, 17-25 (2002).
17. Zhou L, Lu Z, Yang A et al. Comparative proteomic analysis of human pancreatic juice: methodological study. Proteomics 7, 1345-1355 (2007).
18. Yan L, McFaul C, Howes N et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 128, 2124-2130 (2005).
19. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann. Intern. Med. 131(4) 247-255 (1999). Erratum: Ann. Intern. Med. 132, 419 (2000).
20. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-19 as a screening test for pancreatic cancer in an asymptomatic population. J. Gastroenterol. Hepatol. 19, 182-186 (2004).
21. Koopmann. J, Rosenzweig CN, Zhang Z et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin. Cancer Res. 12, 442-446 (2006).
22. Melle C, Ernst G, Escher N et al. Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin. Chem. 53, 629-635 (2007).
23. Laird PW. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3, 253-266 (2003). •• Excellent overview of the use of methylation markers for diagnostic purposes.
24. Leung WK, To KF, Man EP et al. Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study. Clin. Chem. 50, 2179-2182 (2004).
25. Leung WK, To KF, Man EP et al. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am. J. Gastroenterol. 100, 2274-2279 (2005).
26. Wang JY, Hsieh JS, Chang MY et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J. Surg. 28, 721-726 (2004).
27. Silva JM, Dominguez G, Garcia JM et al. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res. 59, 3251-3256 (1999).
28. Leung WK, To KF, Man EP et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am. J. Gastroenterol. 102, 1070-1076 (2007).
29. Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology 127, 422-427 (2004).
30. Vernon SW. Participation in colorectal cancer screening: a review. J. Natl Cancer Inst. 89, 1406-1422 (2003).
31. Maitra A, Fukushima N, Takaori K, Hruban RH. Precursors to invasive pancreatic cancer. Adv. Anat. Pathol. 12, 81-91 (2005).
32. Cubilla AL, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res. 36, 2690-2698 (1976). •• Provides important data on the prevalence of precursors of pancreatic cancer.
33. Kozuka S, Sassa R, Taki T et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer 43, 1418-1428 (1979). •• Provides important data on the prevalence of precursors of pancreatic cancer.
34. Lowenfels AB, Maisonneuve P, Cavallini G et al; International Pancreatitis Study Group. Pancreatitis and the risk of pancreatic cancer. N. Engl. J. Med. 328, 1433-1437 (1993).
35. Brand RE, Lerch MM, Rubinstein WS et al. Participants of the Fourth International Symposium of Inherited Diseases of the Pancreas. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56, 1460-1469 (2007).
36. Howes N, Lerch MM, Greenhalf W et al. European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC). Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin. Gastroenterol. Hepatol. 2, 252-261 (2004).
37. Wong T, Howes N, Threadgold J et al. Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients. Pancreatology 1, 486-509 (2001).
38. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 54, 3568-3573 (1994).
39. Berndt C, Haubold K, Wenger F et al. K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases. Clin. Chem. 44, 2103-2107 (1998).
40. Wenger FA, Zieren J, Peter FJ, Jacobi CA, Muller JM. K-ras mutations in tissue and stool samples from patients with pancreatic cancer and chronic pancreatitis. Langenbecks Arch. Surg. 384, 181-186 (1999).
41. Lu X, Xu T, Qian J, Wen X, Wu D. Detecting K-ras and p53 gene mutation from stool and pancreatic juice for diagnosis of early pancreatic cancer. Chin. Med. J. (Engl.) 115(11), 1632-1636 (2002).
42. Wu X, Lu XH, Xu T et al. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Chin. J. Dig. Dis. 7, 170-174 (2006).
43. Pezzilli R, Barassi A, Melzi d'Eril G et al. The search of the stool and blood K-ras mutations in patients with pancreatic mass. Pancreas 33, 199-200 (2006).
44. Haug U, Hillebrand T, Bendzko P et al. Mutant-enriched PCR and allele-specific hybridization reaction to detect K-ras mutations in stool DNA: high prevalence in a large sample of older adults. Clin. Chem. 53, 787-790 (2007).
45. Hruban RH, van Mansfeld AD, Offerhaus GJ et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am. J. Pathol. 143, 545-554 (1993).
46. Haug U, Brenner H. New stool tests for colorectal cancer screening: a systematic review focusing on performance characteristics and practicalness. Int. J. Cancer 117, 169-176 (2005).
47. Müller HM, Oberwalder M, Fiegl H et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 363, 1283-1285 (2004). •• First study to demonstrate the feasibility of analyzing methylation markers in fecal DNA.
48. Belshaw NJ, Elliott GO, Williams EA et al. Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 13, 1495-1501 (2004).
49. Leung WK, To KF, Man EP et al. Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study. Clin. Chem. 50, 2179-2182 (2004).
50. Petko Z, Ghiassi M, Shuber A et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin. Cancer Res. 11, 1203-1209 (2005).
51. Lenhard K, Bommer GT, Asutay S et al. Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin. Gastroenterol. Hepatol. 3, 142-149 (2005).
52. Itzkowitz SH, Jandorf L, Brand R et al. Improved fecal DNA test for colorectal cancer screening. Clin. Gastroenterol. Hepatol. 5, 111-117 (2007).
53. Huang ZH, Li LH, Yang F, Wang JF. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J. Gastroenterol. 13, 950-954 (2007).
54. Sato N, Goggins M. The role of epigenetic alterations in pancreatic cancer. J. Hepatobiliary Pancreat. Surg. 13, 286-295 (2006).
55. Goggins M. Molecular markers of early pancreatic cancer. J. Clin. Oncol. 23, 4524-4531 (2005). •• Excellent overview of blood- and pancreatic juice-based markers aiming at the early detection of pancreatic cancer.
56. Olson J, Whitney DH, Durkee K, Shuber AP. DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests. Diagn. Mol. Pathol. 14, 183-191 (2005).
57. Whitney D, Skoletsky J, Moore K et al. Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J. Mol. Diagn. 6, 386-395 (2004).
58. The Sol Goldman Pancreatic Cancer Research Center: The Pancreatic Cancer Early Detection Laboratory www.path.jhu.edu/pancreas/professionals/reGogginslab. php Accessed 15 January 2008.
59. Cancer of the Pancreas Screening Study (CAPS 3) http://clinicaltrials. gov/ct/gui/show/NCT00438906?order=1 Accessed January 2008.